Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 9, n. 4, p. 173–181, 2008. DOI: 10.7175/fe.v9i4.235. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/235. Acesso em: 29 oct. 2025.